Similarly, post-progression survival (Basal-PPS HR=0.28 P<0.001) and distant metastasis-free survival (Basal-DMFS HR=0.56 P<0.001) both showed significantly reduced survival times in the low-expression group (Fig. 2D-E), emphasizing the potential of LCP1 as a positive prognostic biomarker for patients with basal-like breast cancer. This evidence concerns the gene LCP1 and breast carcinoma.